evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,835 questions · 1,886 findings · 74 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 542 · 28.7%GRADE not reported 130 · 6.9%Very low 326 · 17.3%Low 434 · 23%Moderate 348 · 18.5%High 106 · 5.6%

Intervention not reported

Clinical score of dryness Hahnel 2017: measured at day 56 ± 4 using the Overall Dry Skin Score Boccanfuso 1978: measured after 10 applications using a non‐validated General Foot Condition Questionnaire including a Dryness Scale (1 = oily; 2 = norm... · people 60 years of age and older
1 finding from 1 review

Any systemic treatment vs placebo

Infliximab · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher infliximab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Tildrakizumab · people with chronic plaque psoriasis

Any systemic treatment leads to higher tildrakizumab compared with placebo (high certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Oral Tyrosine kinase 2 (TYK2) inhibitor · people with chronic plaque psoriasis

Any systemic treatment may leads to higher oral tyrosine kinase 2 (TYK2) inhibitor compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Certolizumab · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher certolizumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Ciclosporin · people with chronic plaque psoriasis

It is very uncertain whether any systemic treatment changes ciclosporin compared with placebo (very low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Etanercept · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Methotrexate · people with chronic plaque psoriasis

Any systemic treatment may leads to higher methotrexate compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Tofacitinib · people with chronic plaque psoriasis

Any systemic treatment may leads to higher tofacitinib compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Apremilast · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher apremilast compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Acitretin · people with chronic plaque psoriasis

It is very uncertain whether any systemic treatment changes acitretin compared with placebo (very low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Ixekizumab · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher ixekizumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Bimekizumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in bimekizumab compared with placebo (low certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Risankizumab · people with chronic plaque psoriasis

Any systemic treatment probably leads to lower risankizumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Ustekinumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in ustekinumab compared with placebo (moderate certainty).

2 findings from 1 review

Any systemic treatment vs placebo

Guselkumab · people with chronic plaque psoriasis

Any systemic treatment showed no clear difference in guselkumab compared with placebo (moderate certainty).

2 findings from 1 review